Biotech · Public company · Thousand Oaks, CA, US
Atara Biotherapeutics, Inc.
Ticker ATRA · SEC CIK 0001604464
Track this companyFree. Adds Atara Biotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials71 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline7
- ATA188Phase 2 · Primary Progressive Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- EBV-specific T cells (EBV-CTLs)Phase 2 · EBV-induced LymphomasClinicalTrials.gov · fetched Nov 12, 2026
- Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)Phase 2 · EBV-induced LymphomasClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 2 · Nasopharyngeal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- TabelecleucelPhase 2 · Nasopharyngeal CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- ATA3219Phase 1 · Relapsed/Refractory B-cell Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- ATA3219Phase 1 · Lupus NephritisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus ErythematosusPHASE1 · WITHDRAWN · started Apr 16, 2025ClinicalTrials.gov NCT06429800 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaPHASE1 · TERMINATED · started Sep 6, 2024ClinicalTrials.gov NCT06256484 · fetched Nov 12, 2026
- Mesothelin-targeted CAR T-cell Therapy in Patients With MesotheliomaPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 30, 2020ClinicalTrials.gov NCT04577326 · fetched Nov 12, 2026
- Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)PHASE1_PHASE2 · TERMINATED · started Feb 19, 2019ClinicalTrials.gov NCT03769467 · fetched Nov 12, 2026
- Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple SclerosisPHASE1_PHASE2 · TERMINATED · started Oct 19, 2017ClinicalTrials.gov NCT03283826 · fetched Nov 12, 2026
- Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated MalignanciesPHASE2 · COMPLETED · started Dec 1, 2011ClinicalTrials.gov NCT01498484 · fetched Nov 12, 2026
- Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or MalignanciesPHASE1_PHASE2 · COMPLETED · started Mar 1, 1995ClinicalTrials.gov NCT00002663 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 26, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jun 12, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 7, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 1, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 16, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 16, 2026 · fetched Nov 12, 2026